Zacks: Brokerages Anticipate Core Laboratories (NYSE:CLB) Will Post Earnings of $0.15 Per Share

Analysts expect Core Laboratories (NYSE:CLBGet Rating) to announce earnings per share (EPS) of $0.15 for the current quarter, Zacks reports. Zero analysts have issued estimates for Core Laboratories’ earnings, with the lowest EPS estimate coming in at $0.06 and the highest estimate coming in at $0.18. Core Laboratories also reported earnings of $0.15 per share during the same quarter last year. The firm is scheduled to announce its next quarterly earnings report after the market closes on Monday, January 1st.

On average, analysts expect that Core Laboratories will report full-year earnings of $0.99 per share for the current financial year, with EPS estimates ranging from $0.89 to $1.03. For the next fiscal year, analysts anticipate that the business will post earnings of $1.48 per share, with EPS estimates ranging from $1.40 to $1.57. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Core Laboratories.

Core Laboratories (NYSE:CLBGet Rating) last released its quarterly earnings data on Wednesday, February 2nd. The oil and gas company reported $0.20 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.20. The business had revenue of $125.14 million during the quarter, compared to analysts’ expectations of $122.39 million. Core Laboratories had a return on equity of 21.03% and a net margin of 4.20%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.18 EPS.

Several research analysts have recently issued reports on the company. Morgan Stanley upped their price objective on Core Laboratories from $30.00 to $35.00 and gave the stock an “equal weight” rating in a research report on Monday. StockNews.com initiated coverage on Core Laboratories in a report on Thursday, March 31st. They issued a “hold” rating for the company. Three research analysts have rated the stock with a sell rating and three have issued a hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $31.30.

NYSE:CLB opened at $31.83 on Tuesday. The stock has a 50-day simple moving average of $29.31 and a 200-day simple moving average of $27.31. The stock has a market cap of $1.47 billion, a P/E ratio of 74.02 and a beta of 2.79. Core Laboratories has a 1 year low of $21.08 and a 1 year high of $49.87. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.58 and a current ratio of 2.08.

The company also recently announced a quarterly dividend, which was paid on Monday, March 7th. Stockholders of record on Monday, February 14th were issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.13%. The ex-dividend date was Friday, February 11th. Core Laboratories’s payout ratio is currently 9.30%.

Several institutional investors have recently bought and sold shares of CLB. Ariel Investments LLC raised its stake in Core Laboratories by 83.2% during the 4th quarter. Ariel Investments LLC now owns 7,804,307 shares of the oil and gas company’s stock valued at $174,114,000 after acquiring an additional 3,544,659 shares during the last quarter. BlackRock Inc. increased its position in Core Laboratories by 4.3% during the 4th quarter. BlackRock Inc. now owns 5,362,893 shares of the oil and gas company’s stock worth $119,645,000 after purchasing an additional 220,983 shares during the period. State Street Corp increased its position in Core Laboratories by 3.5% during the 4th quarter. State Street Corp now owns 1,136,699 shares of the oil and gas company’s stock worth $25,368,000 after purchasing an additional 38,409 shares during the period. Fisher Asset Management LLC increased its position in Core Laboratories by 40.4% during the 4th quarter. Fisher Asset Management LLC now owns 837,079 shares of the oil and gas company’s stock worth $18,675,000 after purchasing an additional 240,721 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of Core Laboratories by 382.2% in the 4th quarter. Marshall Wace LLP now owns 835,491 shares of the oil and gas company’s stock worth $18,638,000 after acquiring an additional 662,216 shares during the period. 91.72% of the stock is owned by institutional investors and hedge funds.

Core Laboratories Company Profile (Get Rating)

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Featured Stories

Get a free copy of the Zacks research report on Core Laboratories (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.